The notices it replaced
- Reissues: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 2 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 3 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 4 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 5 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-18-574.
Who won it before
3,426 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,225,480,156 in first-year total cost, median $225,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-G (12)]176
- Special Emphasis Panel[ZRG1 SBIB-T (10)]168
- Special Emphasis Panel[ZRG1 ETTN-M (11)]124
- Special Emphasis Panel[ZRG1 RPHB-C (10)]115
- Special Emphasis Panel[ZRG1 IDM-V (12)]112
Most frequent institutions
- AFFINERGY, LLC22
- PANORAMA RESEARCH, INC.22
- PHYSICAL SCIENCES, INC22
- EPICYPHER, INC.18
- PROGENRA, INC.18
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2019 | Completion of IND-package for a novel, non-narcotic painkiller2R44DA041912-03 | YEKKIRALA, AJAY S | BLUE THERAPEUTICS, INC., MA | $1,474,091 | ZRG1 |
| 2019 | Radiation Sterilizable, RFID Tagged Vials for Biomedical Samples2R44OD020162-04 | DAVIDOWITZ, HANANEL | BIO TILLION, LLC, NJ | $999,504 | ZRG1 |
| 2019 | Measuring toxicant effects on cellular function in a microarray format2R42ES026245-02A1 | GUIGNON, ERNEST FITCHLYNES, MICHAEL A | CIENCIA, INC., CT | $500,000 | ZRG1 |
| 2019 | STING Inhibitor Discovery for Rare and Common Autoimmune Diseases1R43AI141819-01 | BANTIA, SHANTASCHWIEBERT, ERIK MILLSSTREIFF, JOHN H | DISCOVERYBIOMED, INC., AL | $300,000 | ZRG1 |
| 2019 | Developing a High-throughput Bioprinting Platform for 3D iPSC-derived Liver Tissues for Early Drug Screening1R43EB026411-01A1 | ZHU, WEI | ALLEGRO 3D, INC., CA | $299,281 | ZRG1 |
| 2019 | Development of a fixed-dose combination therapy for the treatment of chronic musculoskeletal pain1R43AR074369-01 | TOCZKO, MATTHEW ALEXANDER | NEUROCYCLE THERAPEUTICS, INC., MA | $225,531 | ZRG1 |
| 2019 | Using Virtual Reality Psychological Therapy to Develop a Non-Opioid Chronic Pain Therapy1R43NR017575-01A1 | BAEUERLE, TASSILOCEKO, MARTAWEBSTER, LYNN | COGNIFISENSE, INC., CA | $225,000 | ZRG1 |
| 2019 | Material-guided delivery and local activation of bioorthogonal prodrugs1R44GM130240-01 | MEJIA ONETO, JOSE M | TAMBO, INC., CA | $216,910 | ZRG1 |
| 2019 | Online System for Primary Care to Prevent and Address Teen Substance Use1R44DA046262-01 | HARRIS, SION KIMHOWARD, BARBARA JOSTURNER, RAYMOND | TOTAL CHILD HEALTH, INC., MD | $209,799 | ZRG1 |
| 2019 | A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects1R44DA046316-01A1 | KAHN, STUART JZEBALA, JOHN A | SYNTRIX BIOSYSTEMS, INC., WA | $204,489 | ZRG1 |
| 2019 | Screening Device for Autism Spectrum Disorders using High Stimulation Rate ABR with Continuous Loop Averaging Deconvolution1R43DC018430-01 | DELGADO, RAFAEL E | INTELLIGENT HEARING SYSTEMS, FL | $200,092 | ZRG1 |
| 2019 | Quantitative Methane Plume Imager for Localization and Flow Rate Estimation in Mines1R43OH011711-01 | CHEN, SHIN-JUH | PHYSICAL SCIENCES, INC, MA | $149,999 | ZRG1 |
| 2018 | Commercialization of HaploSeq as a Service (HaaS) for generating chromosome-span phased genome and exome sequence information2R44HG008118-04A1 · under PA-16-302 | DIXON, JESSE RLAURENT, LOUISE CHANGSELVARAJ, SIDDARTH | ARIMA GENOMICS, INC., CA | $1,573,140 | ZRG1 |
| 2018 | Peripherally-restricted and long-acting kappa-opioid receptor (LA-KOR) agonists for pain2R44DA042634-02 | RIVIERE, PIERRE | PEPTIDE LOGIC, LLC, CA | $1,524,027 | ZRG1 |
| 2018 | Development of novel small molecule analgesics modulating the nNOS-NOS1AP protein-protein interaction2R44NS098885-02 | FLORIO, STEPHANIE K | ANAGIN, IN | $1,498,044 | ZRG1 |
| 2018 | Device for Treatment of Cardiac No-Option Patients2R44HL129586-02 | HUBBARD, TERRYKASSAB, GHASSAN SWANG, MENGJUN | 3DT HOLDINGS, LLC, CA | $1,432,551 | ZRG1 |
| 2018 | Automation and validation of human on a chip systems for drug discovery2R44TR001326-03 | HICKMAN, JAMES JSHULER, MICHAEL L | HESPEROS, LLC, FL | $1,363,424 | ZRG1 |
| 2018 | Small Molecule Treatments to Enhance Neurological Recovery After Stroke2R44NS095381-02 · under PA-16-302 | FINKLESTEIN, SETH P | STEMETIX, INC., MA | $1,354,461 | ZRG1 |
| 2018 | HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease2R44HL131065-03A1 | BELCHER, JOHN DGOMPERTS, EDWARD | HILLHURST BIOPHARMACEUTICALS, INC., CA | $1,270,298 | ZRG1 |
| 2018 | An add-on microscopy module for fast volumetric imaging2R44MH111463-02A1 | LINNENBERGER, ANNA | MEADOWLARK OPTICS, INC., CO | $1,258,442 | ZRG1 |
| 2018 | Development of a Yellow Fever Vaccine for a Vulnerable Population2R44AI079898-06 · under PA-16-302 | AMANNA, IAN JAMESSLIFKA, MARK K | NAJIT TECHNOLOGIES, INC., OR | $1,248,114 | ZRG1 |
| 2018 | Novel 5-HT7 Antagonists for the treatment of inflammatory bowel disease2R44DK115254-02A1 | BLASS, BENJAMINCANNEY, DANIEL JPIPPIN, DOUGLAS ANTHONY | PRAEVENTIX, LLC, PA | $1,228,145 | ZRG1 |
| 2018 | Multiplexed high-content assay for toxicity profiling using live iPSC-derived cardiomyocyte lines with lineage-specific barcoding2R44TR002572-02 | LUDLAM, MARY | CAIRN BIOSCIENCES, INC., CA | $1,178,386 | ZRG1 |
| 2018 | Micro-imaging catheters for high-resolution, image-guided, endovascular repair of brain aneurysms2R44NS100163-02 | UGHI, GIOVANNI J. | GENTUITY, LLC, MA | $1,168,051 | ZRG1 |
| 2018 | EVVS: Endoscopic Venous Valve System2R44HL137540-02A1 | GALTES, JANET | VENARUM MEDICAL, LLC, NJ | $1,165,363 | ZRG1 |
| 2018 | Accelerated discovery of methylation targeted therapeutic development2R44CA212733-02 | SUN, ZU-WEN | EPICYPHER, INC., NC | $1,148,788 | ZRG1 |
| 2018 | Wearable Vibration Device to Prevent Bone Loss in Postmenopausal Women2R44AG046005-02 · under PA-16-302 | BILEK, LAURA DIANEBURNETT, DANIEL ROGERS | THERANOVA, LLC, CA | $1,146,609 | ZRG1 |
| 2018 | Device for rapid extraction of rare pathogens from raw samples2R44AI124930-02 · under PA-16-302 | FISHER, JAY KENNETH | REDBUD LABS, INC., NC | $1,140,832 | ZRG1 |
| 2018 | Clinical Evaluation of a New Middle Ear Diagnostic to Support FDA Regulatory Clearance2R44DC014599-03 | SHELTON, RYAN L | PHOTONICARE, INC., IL | $1,126,043 | ZRG1 |
| 2018 | A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer2R44CA210817-02 | SERRERO, GINETTE | A AND G PHARMACEUTICAL, INC., MD | $1,101,350 | ZRG1 |
| 2018 | A Device for Measuring Blood Concentrations of Unbound Bilirubin in Neonates2R44HD080412-04A1 | KLEINFELD, ALAN MARC | FLUORESPROBE SCIENCES, LLC, CA | $1,047,363 | ZRG1 |
| 2018 | Ambient light activatable opsin based therapy for age-related macular degeneration2R44EY025905-02A1 | MOHANTY, SAMARENDRA KUMARWRIGHT, WELDON | NANOSCOPE TECHNOLOGIES, LLC, TX | $1,031,182 | ZRG1 |
| 2018 | Sleeping Beauty Engineered B Cells for Mucopolysaccharidosis2R44GM115192-02A1 | HAMPE, CHRISTIANE S | IMMUSOFT CORPORATION, WA | $1,028,903 | ZRG1 |
| 2018 | A Novel Test to Measure Latent Virus in HIV-1 Infected Patients2R44AI124996-02 · under PA-16-302 | LAIRD, GREGORY MICHAEL | ACCELEVIR DIAGNOSTICS, LLC, MD | $1,000,000 | ZRG1 |
| 2018 | Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas2R44AI120392-03A1 | BURNS, CHRISTOPHER JOHN | VENATORX PHARMACEUTICALS, INC., PA | $1,000,000 | ZRG1 |
| 2018 | sHLA Protein Chip2R44AI122642-03 | JAYARAMAN, KRISHNA | GENOMICS USA, INC., TX | $1,000,000 | ZRG1 |
| 2018 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer2R44CA200161-02A1 | SONENSHEIN, GAIL E. | ADECTO PHARMACEUTICALS, INC., MA | $1,000,000 | ZRG1 |
| 2018 | Improved cleaning technology for reducing risk of transmitting infection in endoscopy.2R44AI132040-02 | LABIB, MOHAMED ESOHN, SEO YEAN | ADVANCED BIODEVICES, LLC, NJ | $999,998 | ZRG1 |
| 2018 | A Prognostic Blood Test to Monitor Pancreatic Cancer Treatment by MiRNA Profiling2R44CA199058-02 | SARAF, RAVI | VAJRA INSTRUMENTS, INC., NE | $999,597 | ZRG1 |
| 2018 | Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis2R44DK092005-04 | SHARMA, KUMARTUCCI, FABIO COHEN | EPIGEN BIOSCIENCES, INC., CA | $999,500 | ZRG1 |
| 2018 | Preclinical development of teixobactin, a new antibiotic2R44AI118000-03 | HUGHES, DALLAS | NOVOBIOTIC PHARMACEUTICALS, LLC, MA | $999,040 | ZRG1 |
| 2018 | Development of a kit for the targeted depletion of abundant sequencesfromDNA/RNA libraries2R44AI124933-03 · under PA-16-302 | CARPENTER, MEREDITH LAUREN | ARC BIO, LLC, MA | $998,921 | ZRG1 |
| 2018 | Integrating CNV analysis into a NextGen sequencing clinical analytics platform2R44GM125432-02 | SCHERER, ANDREAS | GOLDEN HELIX, INC., MT | $997,214 | ZRG1 |
| 2018 | Optimization and Validation of an Indicator Cell Assay for Blood-Based Diagnosis of Alzheimer's Disease2R44AG051282-03 | SMITH, JENNIFER JOY | PRECYTE, INC., MD | $996,801 | ZRG1 |
| 2018 | Optimization and Validation of an indicator cell assay for blood-based diagnosis of lung cancer2R44CA203455-02A1 | SMITH, JENNIFER JOY | PRECYTE, INC., MD | $996,232 | ZRG1 |
| 2018 | Phase IIB - Smart Eyewear Assistant for the Support of Seniors and their Caregivers in the Long-term Care Setting2R44AG046969-04 | FAUCI, MARK A | GEN-9, INC., CA | $995,645 | ZRG1 |
| 2018 | Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine2R44AI114331-02A1 · under PA-16-302 | BAGLEY, KENNETH C | PROFECTUS BIOSCIENCES, INC., MD | $993,161 | ZRG1 |
| 2018 | Evaluating the impact of novel inhibitors of nuclear pore export in SLE2R44AI124949-02 · under PA-16-302 | LANDESMAN, YOSEFTAMIR, SHARON | KARYOPHARM THERAPEUTICS, INC., MA | $992,511 | ZRG1 |
| 2018 | Development of Molecular Diagnostic Test for Early Onset of Lyme disease2R44AI114009-02 · under PA-16-302 | SCHUTZER, STEVEN E | BIOSCIENCE DEVELOPMENT, INC., NY | $988,413 | ZRG1 |
| 2018 | Modeling Disease in Swine by Transplantation of Gene Targeted Germ Cells2R44GM108150-02A1 | CARLSON, DANIEL FRED | RECOMBINETICS, INC., MN | $986,749 | ZRG1 |
| 2018 | Aerosol Delivery of Surfactant for ARDS2R44HL127834-02A1 · under PA-16-302 | YEATES, DONOVAN BYRON | KAER BIOTHERAPEUTICS CORPORATION, CA | $986,436 | ZRG1 |
| 2018 | Interstitial Intensity Modulated Photodynamic Therapy Phase II2R44CA213654-02 | POTASEK, MARYSHAFIRSTEIN, GAL | SIMPHOTEK, INC., NJ | $984,904 | ZRG1 |
| 2018 | NAAA Inhibition for Pain and Inflammation2R44NS092123-02A1 | MONAGHAN, EDWARD PAUL | NEOKERA, LLC, MA | $983,494 | ZRG1 |
| 2018 | IOBIO based, distributed genomic data access, management, visualization, and analysis2R44HG009096-02 | MARTH, GABOR TMILLER, CHASEWARD, ALISTAIR | FRAMESHIFT LABS, INC., MA | $982,303 | ZRG1 |
| 2018 | Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD2R44AI104034-05A1 | RASCHKE, WILLIAM C | VIROGENICS, INC., CA | $977,956 | ZRG1 |
| 2018 | Preclinical Development of Oxy200 for the Treatment of Osteoporosis2R44AG055374-04 | STAPPENBECK, FRANK | MAX BIOPHARMA, INC., CA | $975,009 | ZRG1 |
| 2018 | Commercialization of a Software Platform to Increase the Efficiency of Human Clinical Trials using Patient-Level Machine Learning Models2R44TR002047-02 | ENNIST, DAVID L | ORIGENT DATA SCIENCES, INC., VA | $969,314 | ZRG1 |
| 2018 | Rapid and Simple Paper Strip Test for the Multiplexed Detection of Gastrointestinal Pathogens at the Point-of-Need2R44TR001912-02 | HENDERSON, WENDY AKIM, CHANG HEE | GODX, INC., WI | $966,680 | ZRG1 |
| 2018 | Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development2R44CA203090-02 | GAMBHIR, SANJIV SUNGER, EVAN CHARLES | NUVOX PHARMA, LLC, AZ | $963,578 | ZRG1 |
| 2018 | PDE4D PET Ligand2R44MH107077-02A1 | GURNEY, MARK E | TETRA DISCOVERY PARTNERS, INC., MI | $952,592 | ZRG1 |
| 2018 | Development of a Surgical Simulator for Endovascular Access Training2R44HL132665-02 | BEASLEY, RYAN ANDREW | SIMQUEST INTERNATIONAL, LLC, MD | $943,802 | ZRG1 |
| 2018 | Multiplexed Bead-based In Vitro Pediatric Allergy Test2R44AI100424-06 · under PA-16-302 | LIM, MARK | AMBERGEN, INC, MA | $937,987 | ZRG1 |
| 2018 | Automated assessment using facial coding2R44DA042640-02 | NAJAVITS, LISA M | TREATMENT INNOVATIONS, LLC, MA | $930,188 | ZRG1 |
| 2018 | TDP-43 aggregation inhibitors for the treatment of ALS2R44NS095481-03 | LARSEN, GLENNWOLOZIN, BENJAMIN L | AQUINNAH PHARMACEUTICALS, INC., MA | $923,960 | ZRG1 |
| 2018 | Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity2R44DK107018-03A1 | SCHNEYER, ALAN L | FAIRBANKS PHARMACEUTICALS, MA | $920,248 | ZRG1 |
| 2018 | Real-time volumetric specimen imager for 3D intra-operative lumpectomy margin assessment2R44CA206801-02 | HAN, XIAO | CLARIX IMAGING CORPORATION, IL | $920,127 | ZRG1 |
| 2018 | Small Molecule Inhibitors of PCSK9-Phase II2R44HL134462-02 | FEIG, PETER USHAH, SALIM | HINGEZ THERAPEUTICS, INC., VA | $909,169 | ZRG1 |
| 2018 | High-throughput methyltransferase assays using recombinant nucleosome substrates2R44GM117683-02A1 · under PA-16-302 | SUN, ZU-WEN | EPICYPHER, INC., NC | $903,808 | ZRG1 |
| 2018 | Therapeutic Development of RNAi-based inhibitors against the Hepatitis Delta Virus2R44AI104007-02A1 | JOHNSTON, BRIAN H. | SOMAGENICS, INC., CA | $902,942 | ZRG1 |
| 2018 | A preclinical multi-modal system for dynamic noninvasive assessment of liver disease2R44DK112492-02 | CZERNUSZEWICZ, TOMASZ JOSEPHGESSNER, RYAN | SONOVOL, INC., NC | $896,265 | ZRG1 |
| 2018 | Tumor Embolization Using A Novel Catheter With Integrated Flow Regulation2R44CA192428-02A1 | ALLEN, MICHAEL PATRICK | EMBOLX, INC., CA | $893,847 | ZRG1 |
| 2018 | Spatial Genomics for in situ single cell expression analysis in the brain1R43MH115538-01A1 | FRIEDA, KIRSTEN | SPATIAL GENOMICS, INC., CA | $885,468 | ZRG1 |
| 2018 | Development of a novel bioabsorbable clip and applier for rapid closure of the dura mater in open and minimally invasive spine surgery.2R44NS107104-02 | DREILINGER, RACHEL | NEURAMEDICA, LLC, OR | $870,245 | ZRG1 |
| 2018 | A nucleosome sliding assay platform to screen inhibitors of SWI/SNF chromatin remodeling complexes2R44GM123869-02 | KEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $866,168 | ZRG1 |
| 2018 | Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide2R44CA195937-02A1 | GREK, CHRISTINA | XEQUEL BIO, INC., SC | $841,361 | ZRG1 |
| 2018 | Novel genotoxicity assay incorporating the toxicogenomics biomarker TGx-28.65 with a direct digital counting2R44ES026473-02 | FORNACE, ALBERT JGEORGE, JAY | AMELIA TECHNOLOGIES, LLC, DC | $840,491 | ZRG1 |
| 2018 | Rapid Detection of Common Failure Modes for Knee Prosthetics2R44AR067048-02A1 | BILLI, FABRIZIOROSS, GRAHAM | BRUIN BIOMETRICS, LLC, CA | $839,554 | ZRG1 |
| 2018 | Development of a novel highly effective influenza vaccine2R44AI109925-03 · under PA-16-302 | BILSEL, PAMUKSARAWAR, SALLY R. | FLUGEN, INC., WI | $834,285 | ZRG1 |
| 2018 | Large Pore SPP Particles for Protein Separations2R44GM116224-02 | BOYES, BARRY E | ADVANCED MATERIALS TECHNOLOGY, INC., DE | $833,309 | ZRG1 |
| 2018 | Targeted Polymerized Shell Microbubbles to Image and Treat Surgical Adhesions2R44GM116530-02 | NAGY, JON OWENWONG, JOYCE Y | NANOVALENT PHARMACEUTICALS, INC., MT | $831,190 | ZRG1 |
| 2018 | Developing and Evaluating In-Home Supportive Technology for Dementia Caregivers1R44AG059458-01 | WANG, GENE | PEOPLE POWER COMPANY, WA | $825,561 | ZRG1 |
| 2018 | Cancer Imaging and Therapy Analysis Platform (CITAP)2R44CA213601-02 | GARGESHA, MADHUSUDHANAWILSON, DAVID LYNN | BIOINVISION, INC., OH | $817,362 | ZRG1 |
| 2018 | Microhook nerve tape: A nerve repair coaptation aid2R44NS097113-03A1 | CLEMENTS, ISAAC PERRY | AXION BIOSYSTEMS, LLC, GA | $810,116 | ZRG1 |
| 2018 | Responsive eHealth Intervention for Perinatal Depression in Healthcare Settings2R44MH109191-02 | DANAHER, BRIAN G.SEELEY, JOHN RSILVER, RICHARD KARLSMITH, DAVID RANDOLPH | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $801,141 | ZRG1 |
| 2018 | Creating Physical Objects with 3D Printers to Stimulate Reminiscing for Memory Loss2R44AG049548-02A1 | PLOCHER, TOM | MOAI TECHNOLOGIES, LLC, MN | $799,785 | ZRG1 |
| 2018 | Lab-To-Marketplace: Commercialization of a stretchable microelectrode array2R44NS086118-03A1 | GRAUDEJUS, OLIVER | BMSEED, LLC, AZ | $796,856 | ZRG1 |
| 2018 | Improved Silicone Lubrication to Reduce Sub-Visible Particles in Parenteral Containers.2R44EY024461-02A1 | THORNTON, JACKSON D | TRIBOFILM RESEARCH, INC., NC | $796,770 | ZRG1 |
| 2018 | Transdermal H2S Sensing Device for Monitoring Peripheral Artery Disease2R44HL121871-02A1 | KANAGY, NANCY LSHEKARRIZ, REZA | EXHALIX, LLC, NM | $790,092 | ZRG1 |
| 2018 | A technology solution for peer-led Seeking Safety2R44DA041949-02 | NAJAVITS, LISA M | TREATMENT INNOVATIONS, LLC, MA | $789,598 | ZRG1 |
| 2018 | A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis2R44AI126987-02 | ALT, JEREMIAH ANDREWPULSIPHER, ABIGAIL | GLYCOMIRA, LLC, UT | $781,547 | ZRG1 |
| 2018 | Intraoperative Ureter Detection System2R44HD089769-02 | SHUKAIR, SHETHA | BRITESEED, LLC, IL | $780,962 | ZRG1 |
| 2018 | Miniaturized Stopped-Flow Reaction Microcalorimeter for Biomedical Applications2R44GM113279-02A1 · under PA-16-302 | BROWN, RICHARD KENNETH | CAPE BIORESEARCH, INC., MA | $775,488 | ZRG1 |
| 2018 | Over-the-Wire Device for Immediate and Complete Peripheral Artery Occlusion2R44HL124832-02A1 · under PA-16-302 | FRANANO, F. NICHOLAS | ARTIO MEDICAL, INC., KS | $765,897 | ZRG1 |
| 2018 | Tools for the site-specific labeling and immobilization of antibodies for immunoassays2R44EB023750-02 | YU, FEIFAN | ALPHATHERA, INC., PA | $764,390 | ZRG1 |
| 2018 | A smartphone-based point-of-care test for detection of Chlamydia trachomatis2R44AI118180-02 | PATERSON, ANDREW SLATOR | LUMINOSTICS, INC., CA | $761,788 | ZRG1 |
| 2018 | Bactericidal Intravascular Biosensor for Continuous Reading of Lactate in the lCU Ph22R44GM119883-02 | CHEN, HAO | BIOCREDE, INC., MI | $760,088 | ZRG1 |
| 2018 | Developing the required biomarkers that define ferroportin target engagement and impact on downstream signaling for clinical translation2R44HL132702-02 | LIU, DAVID Y | PROTAGONIST THERAPEUTICS, INC., CA | $758,874 | ZRG1 |
| 2018 | An implantable hemodialyzer for treatment of End-stage Renal Disease2R44DK102240-02 | BLAHA, CHARLES | SILICON KIDNEY, LLC, CA | $756,920 | ZRG1 |
| 2018 | Ophthalmic drug delivery using a multi-layer contact lens design that enables targeting, constant-rate release and failure protection2R44EY026850-02A1 · under PA-16-302 | YANG, ARTHUR | LYNTHERA CORPORATION, PA | $754,785 | ZRG1 |
| 2018 | A Phase II trial of abiraterone in combination with PDMX1001 in enzalutamide-resistant prostate cancer2R44CA206668-02A1 | LIU, CHENGFEI | PANDOMEDX, INC., CA | $754,319 | ZRG1 |
| 2018 | High-throughput screening of arrayed single cells for automated analysis of phenotypic heterogeneity2R44GM122149-02 | FORBES, ZACHARY GRAHAM | CELLDOM, INC., CA | $751,561 | ZRG1 |
| 2018 | Deconvolution and Assembly of Metagenomes Using Chromatin Conformation Capture2R44AI122654-02A1 | LIACHKO, IVAN | PHASE GENOMICS, INC., WA | $750,250 | ZRG1 |
| 2018 | Wireless Sensor Inserts for Combating Incontinence-Associated Dermatitis2R44NR014614-02A1 · under PA-16-302 | PROKOPUK, NICHOLAS | JPTECHNOLOGIES, INC., CA | $750,000 | ZRG1 |
| 2018 | A robust heterologous expression system of intact fungal secondary metabolite gene clusters for natural product discovery in Aspergillus nidulans2R44AT009158-02 | BOK, JIN WOOKELLEHER, NEIL LWU, CHENGCANG CHARLES | INTACT GENOMICS, INC., MO | $750,000 | ZRG1 |
| 2018 | Automated image-based biomarker computation tools for diabetic retinopathy2R44TR000377-05 | SOLANKI, KAUSHAL | EYENUK, INC., CA | $750,000 | ZRG1 |
| 2018 | A Biodegradable Vascular Coupling Device for End-to-End Anastomosis2R44HL132767-02A1 | AGARWAL, JAYANT PRASADGALE, BRUCELI, HUIZHONGSANT, HIMANSHU | MICROSURGICAL INNOVATIONS, INC., UT | $750,000 | ZRG1 |
| 2018 | An Open Web Service For Fragment-based Design of Small Molecule Inhibitors2R44GM109549-02A1 | KULP, JOHN L | CONIFER POINT PHARMACEUTICALS, LLC, PA | $749,999 | ZRG1 |
| 2018 | Development of new anti-epilepsy treatments targeting cellular energetics through mitochondrial modulation with optimal pharmacokinetics and toxicity profiles2R44NS097047-02 | CHAN, SHERINE SHIMES, RICHARD A | NEUROENE THERAPEUTICS INC, DC | $749,959 | ZRG1 |
| 2018 | An Ultrasensitive, High-Throughput, and Low-Cost Autoimmunity Panel for the Early Diagnosis and Improved Treatment of Type 1 Diabetes2R44DK111005-02 | SEFTEL, DAVID | ENABLE BIOSCIENCES, INC., CA | $749,838 | ZRG1 |
| 2018 | A Novel Lipotherapy to Reduce Infarct Size Following Myocardial Infarction2R44HL132649-02 | BAUER, PHILIPMALDONADO, CLAUDIOTANG, XIAN-LIANG | ENDOPROTECH, INC., KY | $749,712 | ZRG1 |
| 2018 | Development of a Low-Profile Dual Hormone Patch Pump with Novel Occlusion Sensor2R44DK110972-02 | PAYNE, FORREST | SFC FLUIDICS, LLC, AR | $748,973 | ZRG1 |
| 2018 | Additive Manufacturing of Ceramic Dental Restorations2R44DE025803-02A1 | KUTSCH, JEFFREY J | TECHNOLOGY ASSESSMENT AND TRANSFER, INC., MD | $748,795 | ZRG1 |
| 2018 | The Variant Explorer: a cloud-based data integration and visualization system for improving clinical interpretation of sequenced genetic variants.2R44GM117644-02 · under PA-16-302 | XU, XING | SOLVE, INC., NY | $748,556 | ZRG1 |
| 2018 | High-throughput nanoMEA-based Proarrhythmia Assay2R44HL131169-02A1 | GEISSE, NICHOLAS ANDREW | CURI BIO INC, WA | $748,435 | ZRG1 |
| 2018 | IND-Enabling Studies of ZB716, an Orally Bioavailable SERD2R44CA213462-02 | WANG, GUANGDI | ZENOPHARM, LLC, LA | $748,371 | ZRG1 |
| 2018 | A Graphene Nanoparticle-Based X-ray Computed Tomography Contrast Agent ForSubjects At Risk for Contrast Induced Nephropathy2R44DK112550-02 | SITHARAMAN, BALAJITOUSSAINT, JIMMY DEON | THERAGNOSTIC TECHNOLOGIES, INC., NY | $748,000 | ZRG1 |
| 2018 | Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic2R44HL110448-02A1 | DENNING, GABRIELADOERING, CHRISTOPHER BRADLEY | EXPRESSION THERAPEUTICS, GA | $747,641 | ZRG1 |
| 2018 | Universal VLP-Based Flu Vaccine:Broadly protective (universal) virus-like particle (VLP) based influenza vaccine that can neutralize a broad spectrum of influenza A virus subtypes.2R44AI106145-03 | GALARZA, JOSE M. | TECHNOVAX, INC., NY | $746,924 | ZRG1 |
| 2018 | Mobility Rehab: A Biofeedback System for Mobility Rehabilitation for Older Adults2R44AG056012-02 | EL-GOHARY, MAHMOUD | APDM, INC., OR | $746,713 | ZRG1 |
| 2018 | Enabling electron-induced fragmentation in tandem mass spectrometry2R44GM123855-02 | VOINOV, VALERY G. | E-MSION, INC., OR | $746,325 | ZRG1 |
| 2018 | An intravascular Bioartificial Pancreas (iBAP)2R44DK104299-02 | BLAHA, CHARLES | SILICON KIDNEY, LLC, CA | $746,324 | ZRG1 |
| 2018 | Comprehensive but simple encoding of bioassays to accelerate translational drug discovery2R44TR000185-04A1 · under PA-16-302 | BUNIN, BARRY A | COLLABORATIVE DRUG DISCOVERY, INC., CA | $744,321 | ZRG1 |
| 2018 | Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates2R44AR070088-02A1 | LAPIERRE, LEIGHTON | EVOKE MEDICAL, LLC, KS | $738,612 | ZRG1 |
| 2018 | Expanding the Click City: Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products2R44DA044025-02 | ANDREWS, JUDY AGORDON, JUDITH SARAH | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $732,500 | ZRG1 |
| 2018 | Automated Harness Tightener for Child Safety Seat2R44HD085660-02A1 | RYDBERG, NICK | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $732,443 | ZRG1 |
| 2018 | Three-dimensional testicular cell co-culture model for reproductive toxicity screening2R44ES027374-02 | YIN, LEI | REPROTOX BIOTECH, LLC, GA | $729,931 | ZRG1 |
| 2018 | Blood Flow Velocimetry Using Digital Subtraction Angiography2R44HL132664-02 | SINGH, BIPIN | RADIATION MONITORING DEVICES, INC., MA | $724,960 | ZRG1 |
| 2018 | Mobile App Promoting Sexual Health for Young Black Men who Have Sex with Men2R44MD010324-02A1 | COYLE, KARIN KRISTINAKUHN, TAMARA J. | DFUSION, INC., CA | $724,745 | ZRG1 |
| 2018 | Tools for drug efficacy studies in perfused tissue models2R44TR001286-02 · under PA-16-302 | VUKASINOVIC, JELENA | LENA BIOSCIENCES, INC., GA | $724,224 | ZRG1 |
| 2018 | Development of a TransApical to Aorta Double Lumen Cannula for a Neonate LVAD2R44HL120370-02 | TOPAZ, STEPHEN R | W-Z BIOTECH, LLC, KY | $714,777 | ZRG1 |
| 2018 | PINPOINT: Gaming technology to engage adolescent sickle cell patients in precision pain Phase I2R44MD010746-02 | MYERS, VALERIE H | KLEIN BUENDEL, INC., CO | $700,201 | ZRG1 |
| 2018 | Centralized assay datasets for modelling support of small drug discovery organizations2R44GM122196-02A1 | EKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $694,172 | ZRG1 |
| 2018 | Effect of Repeated Administration of G-CSF on Hot Flashes and Other Vasomotor Symptoms of Menopause1R43AG056209-01A1 · under PA-16-302 | DUKE, RICHARD C | MENOGENIX, INC., CO | $693,360 | ZRG1 |
| 2018 | Developing a prenatal biologic therapy to mitigate ASD risk from maternal autoantibodies to Caspr22R44HD092128-02 | BURCH, RONALD M | SPARK2FLAME, INC., NY | $677,502 | ZRG1 |
| 2018 | Optical Dosimeter-guided Photodynamic Therapy2R44CA213607-02 | ZHAO, YOUBO | PHYSICAL SCIENCES, INC, MA | $674,353 | ZRG1 |
| 2018 | Non-Invasive Intraoral LED Phototherapy Device for the Prevention and Treatment of Oral Mucositis2R44DE026082-02A1 | KOTHARI, VEDANG P | LUMITEX, INC., OH | $669,673 | ZRG1 |
| 2018 | Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative2R44ES022885-02 | MAJUMDAR, SUDIPTO | COMPACT MEMBRANE SYSTEMS, INC., DE | $664,015 | ZRG1 |
| 2018 | A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation2R44GM117657-02 | RUPPERT, DAVID | DEEP BLUE MEDICAL ADVANCES, INC., NC | $644,589 | ZRG1 |
| 2018 | miR-SEQ: Highly efficient targeted quantification of extracellular miRNAs by Next Generation Sequencing2R44GM115124-03 · under PA-16-302 | BARBERAN-SOLER, SERGIO | SOMAGENICS, INC., CA | $623,228 | ZRG1 |
| 2018 | High Subzero Equilibrium VCA Cryopreservation2R44AI124835-02 | TAYLOR, MICHAEL JOHNUYGUN, KORKUT | SYLVATICA BIOTECH, INC., SC | $622,651 | ZRG1 |
| 2018 | Caminamos: A location-based Smartphone App for Latinas to Connect with Nearby Walking Partners2R44MD009652-02 | MYERS, VALERIE H | KLEIN BUENDEL, INC., CO | $619,156 | ZRG1 |
| 2018 | Clinical optical coherence tomography for retinal metabolic imaging2R44EY026466-02 · under PA-16-302 | KURANOV, ROMAN | OPTICENT, INC., IL | $617,592 | ZRG1 |
| 2018 | A Point of Care Test to Monitor and Promote Adherence to PrEP for HIV Prevention2R44MH114864-02 | DAUGHTRIDGE, GIFFIN | URSURE, INC., PA | $613,679 | ZRG1 |
| 2018 | Self-advocacy training for students with cochlear implants entering higher education2R44DC013503-02 | HOLTZ, KRISTEN D | KDH RESEARCH AND COMMUNICATION, INC., GA | $612,952 | ZRG1 |
| 2018 | Rapid response toxicology prediction platform2R44ES026909-02 · under PA-16-302 | MYATT, GLENN JOHN | LEADSCOPE, INC., OH | $612,360 | ZRG1 |
| 2018 | Splice sensors for cancer drug discovery2R44CA206804-02 | SOMALINGA, BALAJEE | LUCERNA, INC., NY | $603,137 | ZRG1 |
| 2018 | GUANIDINIUM DERIVATIVES FOR THE TREATMENT OF OCULAR PAIN2R44EY025921-02 | DELWIG, ANTON | SITEONE THERAPEUTICS, INC., CA | $601,128 | ZRG1 |
| 2018 | CFI Pathogen Inactivation of Human Plasma Units1R44HL137605-01A1 · under PA-16-302 | CASTOR, TREVOR P.OCHIENG, WASHINGTONE | APHIOS CORPORATION, MA | $599,617 | ZRG1 |
| 2018 | Monoclonal antibody for autoimmune disease2R44AI120433-02 | LARRICK, JAMES W | PANORAMA RESEARCH, INC., CA | $592,822 | ZRG1 |
| 2018 | HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer2R44GM123833-02 | LOWERY, ROBERT G | BELLBROOK LABS, LLC, WI | $591,712 | ZRG1 |
| 2018 | Plastic Parenteral Containers With Superior Oxygen Barrier Properties2R44HL129622-02 | JONSEN, DANIEL EVERETT | TRIBOFILM RESEARCH, INC., NC | $585,808 | ZRG1 |
| 2018 | Low-temperataure plasma decontamination of pharmaceutical manufacturing fill/finish operations2R44TR001847-02 · under PA-16-302 | GALBALLY-KINNEY, KRISTIN L | PHYSICAL SCIENCES, INC, MA | $583,124 | ZRG1 |
| 2018 | Protect Yourself! Abuse Prevention for People with Intellectual Disabilities2R44HD079119-02 | SHEEHAN, MARTIN R. | DOUBLE S INSTRUCTIONAL SYSTEMS, OR | $572,386 | ZRG1 |
| 2018 | Improving Patient Outcomes through Tracking and Displaying the Disinfection Status of Equipment and Area2R44NR016638-02 · under PA-16-302 | STIBICH, MARK A | XENEX DISINFECTION SERVICES, LLC, TX | $564,057 | ZRG1 |
| 2018 | An Integrative Approach to Control Group Creation for Prevention Research2R44AA024657-02 | HANSEN, WILLIAM B. | PREVENTION STRATEGIES, LLC, NC | $554,976 | ZRG1 |
| 2018 | New Technology to Improve Chemotherapy Safety for Cancer Patients and Health Workers1R43CA224598-01 · under PA-16-302 | SUNKARA, PRASAD | J AND J SOLUTIONS, INC., IA | $548,377 | ZRG1 |
| 2018 | Durable hydrophilic coating to promote effective condom use2R44HD089856-02 | CHIN, STACY L | HYDROGLYDE COATINGS, LLC, MA | $542,627 | ZRG1 |
| 2018 | Deploying retinal birefringence imaging in to the clinic for pediatric vision screening2R44EY027633-02 | BIRCH, EILEEN ELIZABETHSHAKA, JUSTIN | REBISCAN, LLC, MA | $542,407 | ZRG1 |
| 2018 | Selective inhibition of CYP26A1 in the skin for the treatment of ichthyosis2R44AR069416-02 | ASTRUC DIAZ, FANNY | DERMAXON, LLC, MT | $536,029 | ZRG1 |
| 2018 | A Computer Tool for Aiding in Accurate Assessment of Indeterminate Lung Nodules2R44CA203058-02A1 · under PA-16-302 | MENG, XIN | INTERNATIONAL INTELLIGENT INFOR/SOLU/LAB, PA | $529,613 | ZRG1 |
| 2018 | Multi-modal AO-LSO Phase Gradient Imaging of the Inner Retina2R44EY023481-02 · under PA-16-302 | FERGUSON, R DANIEL | PHYSICAL SCIENCES, INC, MA | $527,107 | ZRG1 |
| 2018 | Use of DNATrax and high fidelity computational methods to model transport of contaminants in urban environments2R44ES025070-02 · under PA-16-302 | ZOGRAFOS, ANTONIOS | SAFETRACES, INC., CA | $523,978 | ZRG1 |
| 2018 | Low-cost Personal Sampling Pump2R44OH010635-02A1 | MILLER-LIONBERG, DANIEL D | ACCESS SENSOR TECHNOLOGIES, LLC, CO | $520,322 | ZRG1 |
| 2018 | Advancing Human Health by Lowering Barriers to Electrophysiology in Genetic Model Organisms2R44GM119906-02 · under PA-16-302 | LOCKERY, SHAWN RMCCORMICK, KATHRYN EROBERTS, WILLIAM MWEEKS, JANIS C | NEMAMETRIX, INC., OR | $510,448 | ZRG1 |
| 2018 | Confocal and Autofluorescence Imaging of Macular Degeneration using a Low Cost Digital Imager2R44EY024186-02A1 · under PA-16-302 | MULLER, MATTHEW S | AEON IMAGING, LLC, IN | $505,350 | ZRG1 |
| 2018 | Fully automated enzymatic radiolabeling of biomolecules2R44EB023782-02A1 | DRAKE, CHRISTOPHER RICHARD | SOFIE BIOSCIENCES, INC., CA | $501,151 | ZRG1 |
| 2018 | Novel Polymer Matrix for Dental Applications2R44DE024013-02 | BOLSKAR, ROBERT D | TDA RESEARCH, INC., CO | $500,001 | ZRG1 |
| 2018 | Fast, quantitative analysis of trichloroethylene (TCE) in water2R44ES026513-02A1 | PETERMAN, MARK C | ONDAVIA, INC., CA | $500,000 | ZRG1 |
| 2018 | Development of a Numerical Model for Microbubble Enhanced Treatment in HIFU Therapy2R44CA213866-02 | HSIAO, CHAO-TSUNG | DYNAFLOW, INC., MD | $500,000 | ZRG1 |
| 2018 | Expressive Speech Synthesis for Speech-Generating Devices2R44DC014173-02A1 | HERTZ, SUSAN R | SYNFONICA, LLC, NY | $499,999 | ZRG1 |
| 2018 | Improving drug safety for pregnant women by delivering current and authoritative information via mobile devices2R44DD001127-02 · under PA-16-302 | MARKHAM, GLEN | RIGHTANSWER.COM, INC., MI | $499,961 | ZRG1 |
| 2018 | Evaluation of National Video Directly Observed Therapy Implementation2R44MD010521-03A1 | SEIGUER, SEBASTIANSHAH, MAUNANK | EMOCHA MOBILE HEALTH, INC., MD | $499,597 | ZRG1 |
| 2018 | A Tool to Improve Evaluation of Patient Navigation Services in Underserved Populations2R44MD011350-02 | BURHANSSTIPANOV, LINDA | NATIVE AMERICAN CANCER INITIATIVES, INC., CO | $499,535 | ZRG1 |
| 2018 | Long non-coding RNA signatures to distinguish fibromyalgia syndrome from rheumatic diseases2R44AI129147-02 | AUNE, THOMAS M.SPURLOCK, CHARLES FLOYD | IQUITY LABS, INC, TN | $498,258 | ZRG1 |
| 2018 | Glycoprotein Immunoassay to Measure Protective Response to Lassa Vaccine1R43AI138836-01 | BOISEN, MATTHEW L | ZALGEN LABS, LLC, MD | $497,084 | ZRG1 |
| 2018 | Development of immunoassays for highly sensitive diagnostic monitoring of traumatic brain injury using novel astroglial injury-defined biomarkers1R43NS106972-01 | VANMETER, TIMOTHY E | IMMUNARRAY USA, INC., VA | $496,078 | ZRG1 |
| 2018 | Ultra-Bright Fluorescent Probes for Flow Cytometry2R44GM126848-02 | YU, JIANGBO | LAMPROGEN, INC., WA | $494,939 | ZRG1 |
| 2018 | A New Rapid DNA Platform for Neonatal Sepsis Diagnostics2R44HD084019-02A1 | HODKO, DALIBOR | NEXOGEN, INC., CA | $494,099 | ZRG1 |
| 2018 | Chitosan Gastrointestinal Hemostatic Dressing2R44DK104564-02A1 | ENESTVEDT, BRINTHA KMCCARTHY, SIMON JOHNXIE, HUA | TRICOL BIOMEDICAL, INC., OR | $493,894 | ZRG1 |
| 2018 | Enhanced Treatment Management of Opioid-Dependence in an Office-Based Setting2R44DA033702-02 | MATTAI, ANAND | MEDICASAFE, INC., NY | $491,331 | ZRG1 |
| 2018 | A Direct-Reading Liquid Crystal Based Formaldehyde Dosimeter for Personal Exposure Monitoring2R44ES026474-02 | BEDOLLA PANTOJA, MARCO A | PLATYPUS TECHNOLOGIES, LLC, WI | $487,008 | ZRG1 |
| 2018 | Quantitative Analysis of Single Molecule Microscopy2R44GM121113-02 | CHAO, YEN-CHING | ASTERO TECHNOLOGIES, LLC, TX | $486,798 | ZRG1 |
| 2018 | Sustained Release Travoprost Implant for Treatment of Glaucoma2R44EY028822-02A1 | MANDELL, KENNETH J | LAYERBIO, INC., MA | $485,176 | ZRG1 |
| 2018 | Transvascular access and aspiration of thoracic duct lymph using a novel ultrasound guided approach.2R44DK109876-02A1 | CALLAGHAN, MATTHEW | LXS, INC., CA | $483,956 | ZRG1 |
| 2018 | A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease1R43DK117726-01A1 | FANGER, GARY | RISE THERAPEUTICS, LLC, MD | $480,497 | ZRG1 |
| 2018 | Development and validation of a novel non-invasive device for measuring the mechanical properties of cortical bone1R43AG058312-01 · under PA-16-302 | CLARK, BRIAN CDICK, ANDREWLOUCKS, ANNE B | OSTEODX INC., OH | $477,486 | ZRG1 |
| 2018 | Advanced Indoor Navigation Aid for Blind and Visually-Impaired Individuals in Unfamiliar Spaces2R44EY029213-02 | SCHAEFER, PHILIP R | VORTANT TECHNOLOGIES, LLC, NC | $473,472 | ZRG1 |
| 2018 | MULTI-REPORTER ISOBARIC LABELING REAGENTS FOR INCREASED MULTIPLEXING IN QUANTITATIVE PROTEOMICS2R44GM121157-02 | BRAUN, CRAIG RONALDERICKSON, BRIAN KEITH | IQ PROTEOMICS, LLC, MA | $463,440 | ZRG1 |
| 2018 | IND-enabling Epicardial Biopharmaceutical in the Diabetic Heart1R44HL140649-01A1 | RUIZ-LOZANO, PILAR | REGENCOR, INC., CA | $444,786 | ZRG1 |
| 2018 | Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery1R43GM130268-01 | BORDBAR, AARASHNEMKOV, TRAVIS | SINOPIA BIOSCIENCES, INC., CA | $442,427 | ZRG1 |
| 2018 | A Computer Model of Renal Physiology for use as a FDA Medical Device Development Tool2R44FD005669-02 · under PA-16-302 | PRUETT, WILLIAM ANDREW | HC SIMULATION, LLC, MS | $441,039 | ZRG1 |
| 2018 | PIKFYVE antagonism as a therapy for C9ORF72-ALS/FTD1R44NS105156-01 · under PA-16-302 | ALWORTH, SAMUEL VZHOU, HONGYAN | ACURASTEM, INC., CA | $433,105 | ZRG1 |
| 2018 | HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II2R44HL137514-02 | REED, GUY L | TRANSLATIONAL SCIENCES, INC., AZ | $423,216 | ZRG1 |
| 2018 | Novel Biological Tissue for Vascular Patch1R43HL140763-01A1 | KASSAB, GHASSAN SLU, XIAOWANG, MENGJUN | 3DT HOLDINGS, LLC, CA | $419,085 | ZRG1 |
| 2018 | DEVELOPMENT OF A PEDIATRIC CARDIAC AND RESPIRATORY ASSIST SYSTEM1R43HL144214-01 | DASSE, KURT A | INSPIRED THERAPEUTICS, LLC, VA | $415,921 | ZRG1 |
| 2018 | Development of an Anti-Embolic Micromesh Carotid Stent1R43HL140895-01 · under PA-16-302 | KEALEY, COLIN PATRICK | NEUROSIGMA, INC., CA | $415,743 | ZRG1 |
| 2018 | New-Generation of Fluorescently-Labeled Charge-Neutralized Oligonucleotides as Probes for the Detection and Quantification of MicroRNAs and Oligonucleotide-Based Therapeutics in Biological Samples1R43GM130187-01 | TABATADZE, DAVID R | ZATA PHARMACEUTICALS, INC., MA | $402,225 | ZRG1 |
| 2018 | HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients1R44HL142389-01 | KAHN, STUART JMAEDA, DEAN YOSHIMASA | SYNTRIX BIOSYSTEMS, INC., WA | $398,444 | ZRG1 |
| 2018 | Preclinical Testing of Splice Modulating Oligonucleotides Targeting SCN8A to Treat Dravet Syndrome1R43NS105291-01 · under PA-16-302 | TALLENT, MELANIE K | LIFESPLICE PHARMA, LLC, PA | $389,793 | ZRG1 |
| 2018 | Introducing Neuroscience and Neurocomputation Concepts to High School Students using Brain-based Neurorobots1R43NS108850-01 | GAGE, GREGORY JOHNHARRIS, CHRISTOPHER AIDAN | BACKYARD BRAINS, INC., MI | $386,013 | ZRG1 |
Showing the 200 most recent of 3,426 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.